Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
Authors:
Open Access
- 14 October 2022
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 34 (1) , 189-199
Abstract
Summary In this randomized, controlled trial, sequential therapy with once-weekly subcutaneous injection of teriparatide for 72 weeks, followed by alendronate for 48 weeks resulted in a significantly lower incidence of morphometric vertebral fracture than monotherapy with alendronate for 120 weeks in women with osteoporosis at high risk of fracture. Purpose To determine whether the anti-fracture efficacy of sequential therapy with teriparatide, followed by alendronate is superior to that of monotherapy with alendronate, a prospective, randomized, open-label, blinded-endpoint trial was performed. Methods Japanese women aged at least 75 years were eligible for the study, if they had primary osteoporosis and if they were at high risk of fracture. Patients were randomly assigned (1:1) to receive the sequential therapy (once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks, followed by alendronate for 48 weeks) or monotherapy with alendronate for 120 weeks. The primary endpoint in the final analysis was the incidence of morphometric vertebral fracture during the 120-week follow-up period. Results Between October 2014 and June 2020, 505 patients in the sequential therapy group and 506 in the monotherapy group were enrolled. Of these, 489 and 496, respectively, were included in the main analysis. The incidence of morphometric vertebral fracture during the 120-week follow-up period in the sequential therapy group (64 per 627.5 person-years, annual incidence rate 0.1020) was significantly lower than that in the monotherapy group (126 per 844.2 person-years, annual incidence rate 0.1492), with a rate ratio of 0.69 (95% confidence interval 0.54 to 0.88, P < 0.01). After 72 weeks, no patient had a severe adverse event that was considered related to the study drug. Conclusion Once-weekly injection of teriparatide, followed by alendronate resulted in a significantly lower incidence of morphometric vertebral fracture than alendronate monotherapy in women with osteoporosis who were at high risk of fracture. Trial registration number, date of registration jRCTs031180235 and UMIN000015573, March 12, 2019Keywords
Funding Information
- Public Health Research Foundation
- Asahi Kasei Pharma Corp.
This publication has 23 references indexed in Scilit:
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trialThe Lancet, 2015
- Overlapping and Continued Alendronate or Raloxifene Administration in Patients on Teriparatide: Effects on Areal and Volumetric Bone Mineral Density—The CONFORS StudyJournal of Bone and Mineral Research, 2014
- Diagnostic criteria for primary osteoporosis: year 2012 revisionJournal of Bone and Mineral Metabolism, 2013
- Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trialCurrent Medical Research and Opinion, 2013
- Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture RiskThe Journal of Clinical Endocrinology & Metabolism, 2012
- Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal OsteoporosisCalcified Tissue International, 2011
- Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)Journal of Bone and Mineral Research, 2009
- One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for OsteoporosisNew England Journal of Medicine, 2005
- Assessment of fracture riskOsteoporosis International, 2004
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993